Psyched Wellness Launches Strategic Review to Unlock Shareholder Value

Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) ("Psyched Wellness" or the "Company") , a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, announces that its Board of Directors has commenced a strategic review process designed to evaluate opportunities to enhance and accelerate value creation for shareholders ("Strategic Review"). The Board believes that the Company's current market valuation does not fully capture the commercial progress achieved with Calm®, the growing consumer adoption of AME-1-based products, and the expanding brand ecosystem that now includes Calm®, AMA, and Santa. Together, these brands represent a differentiated and defensible position within the functional wellness category. The Strategic Review will assess a full spectrum of alternatives, including, amongst other things, strategic partnerships, capital infusions, M&A opportunities, a go-private transaction, any other strategic transaction or maintaining the status quo with an optimized growth plan. Psyched Wellness has significantly strengthened e-commerce performance, advanced scientific validation of AME-1, and built a multi-brand platform. Calm continues to gain traction; AMA is establishing a foothold in the adaptogen-forward wellness segment; and Santa is emerging as a playful, approachable entry point for new consumers exploring functional mushroom-based products. These achievements provide a strong foundation for the next stage of growth and potential strategic alignment with larger consumer health, nutraceutical, or CPG platforms. Michael Nederhoff, Interim Chief Executive Officer of Psyched Wellness, stated: "Psyched Wellness has reached an important stage in its development, with Calm®, AMA, and Santa demonstrating strong consumer traction across multiple wellness categories. To support the next phase of scale, the Board believes it is appropriate to explore strategic and financial alternatives - including the potential involvement of the right financial partners, strategic investors, or M&A opportunities - that could strengthen our balance sheet, accelerate commercialization, and unlock the full value of our AME-1 platform. Our goal is to identify the optimal path forward to drive sustainable growth and create meaningful long-term value for our shareholders." The Company has formed a Special Committee to support the Strategic Review. There is no assurance that the process will result in a transaction or any particular outcome, nor is there a defined timeline for completion. Psyched Wellness will continue to operate normally and advance its commercial initiatives throughout the review. Further updates will be provided only if the Board approves a specific transaction or if disclosure is otherwise required under applicable securities laws.